Subscribe
Guidance out to 2028 was reiterated, after operating profit surged by a quarter as expected
A long-awaited rebound in organic growth points to a turnaround in the making
The company will distribute dividends and conduct buybacks this year
Sales at the consumer goods giant were bolstered by a strong showing in emerging markets
Outsourcer beat its free cash flow guidance as new contract wins overpower lower immigration revenue
Tighter NHS commissioning has left a sale as Spire鈥檚 main strategic option
The gold miner still sees a West Africa discount despite moving out of higher-risk areas
The behemoth was once a poster child for industrial decline but there are strong signs of recovery
Weakened growth prospects and customer departures mean it鈥檚 time to cut your losses
Pharma and medtech stocks can offer investors safety if and when Big Tech falters. We highlight where to look
